Riverview Trust Company’s Kura Oncology KURA Stock Holding History

Riverview Trust Company’s Portfolio KURA Stock Details KURA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-2,151	Closed	-$18.7K	–	732
2024 Q4	$18.7K	Buy	+2,151	New	+$31K	0.02%	497

Other funds holding KURA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Riverview Trust Company's KURA Position: Q1 2025 in Review

Riverview Trust Company sold out of Kura Oncology (KURA) in Q1 2025, closing a stake of 2,151 shares — an estimated $18.7K sold.

Riverview Trust Company first reported a position in KURA in Q4 2024 and held it in 1 quarter. The position peaked at $18.7K in Q4 2024. 183 funds tracked by Wall St. Rank hold KURA as of Q1 2025.

Riverview Trust Company reported no remaining Kura Oncology position as of Q1 2025 after selling out during the quarter.
Riverview Trust Company sold 2,151 Kura Oncology shares in Q1 2025, an estimated $18.7K.
Riverview Trust Company first reported a position in Kura Oncology in Q4 2024 and held it in 1 quarter.
Riverview Trust Company's Kura Oncology position peaked at $18.7K in Q4 2024.
183 funds tracked by Wall St. Rank held Kura Oncology as of Q1 2025.

Based on Riverview Trust Company's 13F filing for Q1 2025, filed 11 Apr 2025.